Testing a wearable device that measures night-time scratching in itchy skin conditions
Tests a wearable that detects scratching during sleep in adults with itchy skin conditions.
Plain-language title generated from the registry record
Registry title: Observational Analytical Validation Study of the Replior ScratchSense
Key facts
- Where
- Grenoble, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07909967, who can take part
Where in France
- Eurofins Optimed 1 rue des Essarts, 38610 Gières - FranceGrenoble, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Replior AB
- Trial code
- NCT07909967
- Record updated
- 4 November 2026
- Original description
Nocturnal scratching is a frequent and meaningful symptom in dermatological conditions such as atopic dermatitis. It may reflect underlying disease activity and can substantially disrupt overall sleep and quality of life. Existing approaches to characterizing Nocturnal Scratching-such as self-reports, sleep diaries, and video monitoring-are often subjective, labor-intensive, or lack scalability for widespread use.Read full original descriptionShow less
Observational Analytical Validation Study of the Replior ScratchSense for Nocturnal Scratching Assessment
Nocturnal scratching is a frequent and meaningful symptom in dermatological conditions such as atopic dermatitis. It may reflect underlying disease activity and can substantially disrupt overall sleep and quality of life. Existing approaches to characterizing Nocturnal Scratching-such as self-reports, sleep diaries, and video monitoring-are often subjective, labor-intensive, or lack scalability for widespread use.
Emerging wearable technologies offer an alternative, by enabling objective, continuous, and non- invasive signal related to scratch behavior during sleep.
Inclusion: Male / female participant, aged 18 to 65 years inclusive. Negative pregnancy test at screening for childbearing potential women. Presence of itch-related and/or scratching-inducing conditions: documented or self-reported history of nocturnal itching and scratching, due to conditions such as:; Atopic dermatitis; Chronic pruritus of unknown origin; Other pruritic dermatological or systemic conditions. Expected Nocturnal Scratch activity: participants must: Have experienced Nocturnal Scratching in the past 7 days, and; Be considered likely to scratch during the study period, based on medical history, clinician judgment, or recent self-report.
Exclusion: Recent changes in anti-pruritic treatment: Initiation or dose changes of systemic medications that may suppress nocturnal itch within the past 2 weeks, including: i. Oral corticosteroids ii. Immunosuppressive agents (e.g., cyclosporine, methotrexate) iii. Biologics (e.g., dupilumab) unless on a stable dose ≥8 weeks iv. Sedating antihistamines unless stable for ≥1 week; Topical treatment use: initiation of topical corticosteroids, calcineurin inhibitors, or emollients within 3 days prior to study start, and no use during the study; No current or expected nocturnal itch: well-controlled conditions or no recent reports of nighttime scratching; Confounding movement disorders or sleep conditions: diagnosed restless legs syndrome, periodic limb movement disorder, moderate/severe obstructive sleep apnea, Parkinson's disease, or other conditions that may interfere with motion analysis; Severe psychiatric or cognitive impairment that could impair the ability to consent or comply with the protocol.